Abbasciano V, Levato F, Zavagli G
Institute of Medical Pathology, University of Ferrara, Italy.
Med Oncol Tumor Pharmacother. 1987;4(2):75-9. doi: 10.1007/BF02934943.
In 70 patients affected by gastrointestinal malignancies the plasma fibrinopeptide A (FpA) levels were assessed both before and at various intervals after the operation. At the same time other more commonly used tests of coagulation were carried out. In all the patients plasma FpA levels were shown to be variously elevated, so that they could give useful clues to the diagnosis, treatment, prognosis and follow-up of the gastrointestinal malignancies. In all the patients the coagulation tests fell into the normal ranges. However in the patients affected by recto-sigmoid adenocarcinoma an increase of circulating fibrin degradation products (FDPs) was observed which paralleled the increase of plasma FpA. In conclusion, in gastrointestinal malignancies the increase of plasma FpA levels suggests the cancer-induced start of the coagulation cascade. The assay of this peptide proves to be a reliable marker for these diseases.
对70例胃肠道恶性肿瘤患者在手术前及术后不同时间间隔测定血浆纤维蛋白肽A(FpA)水平。同时进行其他更常用的凝血检测。所有患者血浆FpA水平均有不同程度升高,可为胃肠道恶性肿瘤的诊断、治疗、预后及随访提供有用线索。所有患者的凝血检测结果均在正常范围内。然而,在直肠乙状结肠癌患者中观察到循环纤维蛋白降解产物(FDPs)增加,且与血浆FpA增加平行。总之,在胃肠道恶性肿瘤中,血浆FpA水平升高提示癌症诱导凝血级联反应启动。该肽的检测被证明是这些疾病的可靠标志物。